We are live on ! Find out more
5VM

5AM Venture Management Portfolio holdings

AUM $360M
1-Year Est. Return 345.76%
This Fund
S&P 500
This Quarter Est. Return
+41.74%
1 Year Est. Return
+345.76%
3 Year Est. Return
+491.51%
5 Year Est. Return
+330.26%
10 Year Est. Return
–
AUM
$318M
AUM Growth
+$45.1M
Cap. Flow
-$1.39M
Cap. Flow %
-0.44%
Top 10 Hldgs %
73.5%
Holding
26
New
1
Increased
6
Reduced
2
Closed
5

Top Buys

Rank Stock Value
1
MPLT
MapLight Therapeutics
MPLT
+$15.9M
2
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$5.03M
3
BHVN icon
Biohaven
BHVN
+$3.22M
4
TARA icon
Protara Therapeutics
TARA
+$3.17M
5
TECX
Tectonic Therapeutic
TECX
+$1.77M

Top Sells

Rank Stock Value
1
DNTH icon
Dianthus Therapeutics
DNTH
+$14.4M
2
PRAX icon
Praxis Precision Medicines
PRAX
+$9.01M
3
ALEC icon
Alector
ALEC
+$2.95M
4
CNTA
Centessa Pharmaceuticals
CNTA
+$2.53M
5
ADVM
Adverum Biotechnologies
ADVM
+$2.45M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRAX icon
26
Praxis Precision Medicines
PRAX
$8.52B
– –
-170,000
Closed -$9.01M
1
2

Similar funds

LSC
Logan Stone Capital Chicago, Illinois $360M AUM 9.71% 1-Year Est. Return
WIP
WealthCare Investment Partners Portsmouth, Rhode Island $360M AUM 19.98% 1-Year Est. Return
RA
RR Advisors Dallas, Texas $360M AUM 28.52% 1-Year Est. Return
SWM
SK Wealth Management Providence, Rhode Island $360M AUM 14.81% 1-Year Est. Return
NC
Naman Capital Sao Paulo, Brazil $360M AUM 27.43% 1-Year Est. Return
MCM
Monimus Capital Management Woodbridge, New Jersey $361M AUM 21.17% 1-Year Est. Return
KLWA
Kelly Lawrence W & Associates Pasadens, California $360M AUM 16.9% 1-Year Est. Return
PWC
PYA Waltman Capital Knoxville, Tennessee $361M AUM 9.49% 1-Year Est. Return

5AM Venture Management's Q4 2025 Portfolio in Review

As of Q4 2025, 5AM Venture Management held 26 positions worth $318M, up 17% from $273M the previous quarter. Its ten largest holdings account for 74% of the portfolio.

5AM Venture Management's Q4 2025 filing shows 1 new, 6 increased, 2 reduced and 5 closed positions. Its largest new stake was MapLight Therapeutics: 950,011 shares worth $16.7M. The largest sale was Dianthus Therapeutics, an estimated $14.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • 5AM Venture Management's largest Q4 2025 buy was MapLight Therapeutics: 950,011 shares worth $16.7M.
  • 5AM Venture Management added most to Zentalis Pharmaceuticals in Q4 2025, an estimated $5.03M increase.
  • 5AM Venture Management's biggest Q4 2025 reduction was Centessa Pharmaceuticals, cutting an estimated $2.53M.
  • 5AM Venture Management fully exited Dianthus Therapeutics in Q4 2025, selling an estimated $14.4M.
  • 5AM Venture Management's ten largest holdings make up 74% of its $318M portfolio in Q4 2025.
  • 5AM Venture Management opened 1 new position and closed 5 in Q4 2025.
  • 5AM Venture Management's portfolio value rose 17% quarter-over-quarter to $318M.

Based on 5AM Venture Management's 13F filing for Q4 2025, filed 17 Feb 2026.